Main Uses and Indications

Bronchipret is an herbal medicinal product used for the treatment of inflammatory diseases of the respiratory tract. Its primary application is in the management of acute bronchitis and other respiratory conditions characterized by cough and excessive mucus production.

The medication is designed to address various stages of respiratory inflammation, providing a multifaceted approach to symptom relief without the use of synthetic chemical agents. It is commonly used when symptoms include:

• Acute cough associated with the common cold
• Inflammation of the bronchial tubes (bronchitis)
• Congestion caused by thick, difficult-to-expel phlegm

Therapeutic Benefits and Mechanism

The combination of herbal extracts in Bronchipret works through several mechanisms to support the body’s natural recovery process. The primary therapeutic goals of the treatment are as follows:

Secretolytic and Mucolytic Action

The active ingredients help to thin and loosen thick mucus accumulated in the airways. By reducing the viscosity of the bronchial secretions, the medication makes it easier for the patient to clear the lungs through productive coughing.

Bronchospasmolytic Effect

During inflammatory episodes, the smooth muscles of the bronchi can become constricted, leading to chest tightness and difficulty breathing. Bronchipret helps to relax these muscles, supporting more comfortable breathing and reducing the strain on the respiratory system.

Anti-inflammatory and Antimicrobial Properties

The herbal components possess natural properties that help reduce the inflammatory response in the bronchial mucosa. This reduction in swelling and irritation helps to soothe the airways. Additionally, the formula exhibits activity against various pathogens that commonly trigger or exacerbate respiratory infections.

Reduction of Cough Frequency

By addressing the underlying inflammation and facilitating the removal of mucus, the medication helps to decrease the frequency and intensity of coughing fits. This allows for a more comfortable recovery period and reduces the physical exhaustion often associated with persistent acute bronchitis.

Regulatory References

1. Final European Union herbal monograph on Hedera helix L., folium

Who Can and Cannot Use Бронхипрет?

Population eligibility for Бронхипрет is strictly defined by official regulatory documentation, primarily based on age, physiological status, and pre-existing conditions.

---

Contraindicated and Restricted Populations

Population Group	Regulatory Status
Hypersensitivity	Contraindicated (Allergy to Thyme, Ivy, or excipients).
Pregnancy/Lactation	Not Recommended (Insufficient safety data).
Infants (Syrup)	Not Recommended (Under 1 year of age).
Young Children (Drops)	Not Recommended (Under 6 years of age).
Alcoholism	Restricted (Health risk due to ethanol content).
Gastritis/Stomach Ulcers	Caution Advised (Use requires special consideration).

---

Age-Specific Authorization

Use is authorized for Adults and Adolescents aged 12 years and older. The minimum age for use is 1 year for the Syrup formulation and 6 years for the Drops formulation. Furthermore, use is limited in patients with impaired renal or hepatic function due to insufficient data to establish specific dosage guidelines.

Interactions with other medicines and products

The regulatory documentation for this fixed-dose combination product establishes a defined interaction profile based on official regulatory status. The official prescribing information explicitly states that there are no known interactions with other medicinal products.

Official Regulatory Findings

Interaction Type	Regulatory Status (Label-Based)
Drug–Drug Interactions	None documented. No formal studies on co-administration effects are available.
Metabolic Interactions	None documented. The label contains no information regarding effects on CYP enzymes or drug clearance.
Contraindicated Combinations	None listed.

Product-Substance and Administration Context

Food and Beverages: Regulatory sources confirm that administration may occur with food and drink or independent of meals. No constraints regarding timing separation or reduction of effectiveness due to food are documented in the labeling.

Product-Inherent Substances: The liquid oral solution formulations (syrup and drops) contain alcohol. The concentration of this substance (e.g., 7 vol.-% in the syrup) is a mandatory disclosure in the regulatory text, relating to the product’s inherent composition. This information is a component of the official interaction and substance profile.

The overall structure of the regulatory profile is defined by the absence of documented clinically significant interactions with other medicines, which informs administration guidelines and patient counseling.

The mechanism of action for this phytopharmaceutical combination is defined by two complementary, peripherally acting mechanistic domains that influence the mucociliary transport process through coordinated actions on airway function.

---

Modulation of Airway Secretion and Fluid Balance

This domain is driven primarily by the Ivy leaf extract (alpha-Hederin), which engages mechanisms involving receptor modulation (beta2 adrenergic and M3 muscarinic) on the bronchial epithelium. This interaction initiates a molecular cascade that increases the production of serous fluid and surfactant, reducing the viscosity of secretions and increases the ciliary beat frequency.

---

Reduction of Bronchial Smooth Muscle Tone

The second domain involves the action of the Thyme herb extract (thymol and carvacrol), which targets the smooth muscle surrounding the air passages. These essential oils modulate voltage dependent Ca^2+ channels, reducing the intracellular calcium concentration necessary for muscle contraction. This action leads to a mild bronchial relaxation. This action results in a reduction in airway resistance and acts in parallel with the action on secretion viscosity.

Administration Guidelines for Бронхипрет Syrup TE

This section outlines the administration rules for the syrup formulation (Thyme/Ivy combination).

Route of Administration and Frequency

The medicine is taken orally (by mouth). The frequency is three times daily (in the morning, at midday, and in the evening).

Dosing Schedule

Administration involves using the enclosed measuring cup to ensure accurate dosing. The recommended single dose varies based on age group:

Age Group	Single Dose (ml)	Total Daily Dose (ml)
Children 1 to 5 years	3.2 ml	9.6 ml
Children 6 to 11 years	4.3 ml	12.9 ml
Adults and adolescents ge 12 years	5.4 ml	16.2 ml

Use in children under 1 year of age is not recommended due to the alcohol content and insufficient data.

Preparation and Procedural Steps

1. Shake the bottle well before each use.
2. Dose the medicine using the enclosed measuring cup.
3. Take the dose undiluted or with some water.
4. Afterwards, some liquid (preferably a glass of water, non-alcoholic) can be consumed.

Timing in Relation to Meals

Бронхипрет syrup can be taken together with food and drink or independent of meals. If a sensitive stomach is present, taking the syrup preferably after meals is advised.

Missed Dose Instructions

If a dose is missed, do not take a double dose to make up for the forgotten dose. Instead, continue the treatment by taking the next dose at the regular time.

Research evidence / Overview of Studies for Бронхипрет

---

Evidence for Use in Acute Inflammatory Bronchial Diseases

The research on the active ingredients in Бронхипрет (Ivy leaf and Thyme herb extracts) includes short-term randomized controlled trials (RCTs) and systematic reviews that were used in research exploring how symptoms change over time. Studies focused on patients, including adults and children, with acute inflammation of the bronchi, a condition characterized by episodic manifestations like coughing.

Research examined the outcomes related to overall symptom scores, such as the Bronchitis Severity Score (BSS), over the defined study period. Findings describe patterns observed in the studies and research reported the patterns of symptom measurement in the populations during the short time frame.

---

Evidence for Symptomatic Productive Cough

Research has explored the use of this combination for managing a productive cough, which is associated with acute respiratory tract infections. Studies were conducted during periods of increased symptom activity and focused on outcomes describing episodic or acute changes.

Researchers examined changes in the sputum characteristics, such as its thickness and volume, and the patient's subjective ease of expectoration (clearing phlegm). The findings contribute to understanding how patients reported their experience with cough symptoms during the acute episode.

---

Study Duration and Long-Term Follow-up

Study durations were limited, typically lasting just one to two weeks, which is reflective of the acute nature of the condition studied. Consequently, information regarding long-term outcomes remains limited. Long-term effects are not fully established, and there is limited information on what happens months after the acute episode resolves.

---

Evidence Gaps and Areas of Scientific Uncertainty

The available evidence is derived from studies, primarily short-term trials. Data for certain groups remain insufficient, such as in older adults with multiple pre-existing health conditions. Another area of uncertainty is the variability in extract standardization across the scientific literature. Research is ongoing, and findings contribute to the broader evidence landscape, but certainty remains low regarding outcomes beyond short-term symptomatic management.

Key Studies & References Efficacy and Safety of Bronchipret® TP Tablets in Patients With Acute Bronchitis - A Phase IV Trial (NCT02930263)

Common questions about Бронхипрет (FAQ)

Q: What is the difference between Бронхипрет syrup and the tablets?

A: The official product information indicates that the syrup (TE) and drops primarily contain extracts of Thyme and Ivy. Regulatory documents indicate that the tablets (TP) and drops may contain different combinations and strengths of the active plant extracts compared to the syrup (TE). The various formulations also have specific age restrictions, with tablets generally intended for adolescents and adults.

Q: Does Бронхипрет contain any alcohol?

A: Yes, regulatory documents confirm that liquid formulations of the medicine contain ethanol (alcohol) as an excipient. For example, the Syrup (TE) contains approximately 7 vol.-% alcohol. This mandatory disclosure is important for individuals who have conditions such as alcoholism, liver disease, or epilepsy, as specified in the product's official safety warnings.

Q: What is the typical duration of treatment with Бронхипрет?

A: The duration of use is generally guided by the length of the acute symptoms being treated. Official patient information advises that the medicine should not be used for longer than two weeks without consulting a healthcare professional. If symptoms persist or worsen after this period, it is important to seek consultation from a healthcare professional.

Q: Do many people experience stomach upset or nausea when taking Бронхипрет?

A: Gastrointestinal complaints, such as stomach cramps, nausea, vomiting, or diarrhoea, are known adverse reactions. However, these effects are officially classified as Uncommon in the regulatory safety profile, meaning they affect a low percentage of users (1 to 10 people out of every 1,000).

Q: Does a history of gastritis require caution when taking Бронхипрет?

A: Patients with a history of gastritis or stomach ulcers are advised to use the medicine with caution. This is due to the potential for the product to cause or exacerbate mild gastrointestinal complaints. Official guidance mentions that for a sensitive stomach, taking the syrup preferably after meals is a consideration.

Q: What are the recommended storage temperatures for Бронхипрет?

A: The official storage requirement is that the medicine must not be stored above 25 C. While there is no explicit instruction to store the product in a refrigerator, it must be kept in its original container, protected from light, and tightly closed after each use to maintain stability.

Q: Is there a sugar-free version of Бронхипрет?

A: The excipient lists for some formulations, such as the syrup and tablets, include sugars or sugar substitutes like maltitol. Patients who have dietary restrictions or monitor their sugar intake should always check the list of excipients for their specific formulation.

Q: Is there a maximum number of days Бронхипрет should be used consecutively?

A: Official patient information advises against using the medicine for longer than two weeks consecutively without consulting a healthcare professional. If symptoms persist or return, consultation with a healthcare professional is important.

Q: Is a slight allergic reaction (like a rash) common with herbal cough medicines like Бронхипрет?

A: Allergic reactions are possible with this medicine. However, symptoms such as a skin rash are classified as Rare in the product's regulatory safety profile. More severe reactions like swelling or shortness of breath are considered Very Rare and require immediate cessation and medical review.

Q: Why is the taste of Бронхипрет sometimes described as strong or herbal?

A: The medicine contains concentrated fluid extracts from Thyme herb and Ivy leaves. The strong, distinct herbal taste and odor are due to the presence of natural essential oils, such as thymol, derived from the active plant constituents.

Q: What are the inactive ingredients in Бронхипрет syrup?

A: According to the official list of excipients, the syrup typically contains ingredients such as purified water, glycerol, ethanol, citric acid monohydrate, concentrated ammonia solution, and a sweetening agent like saccharin sodium.

Q: Does Бронхипрет interact with blood pressure medications?

A: Regulatory documents explicitly state that there are no known interactions with other medicinal products reported for this combination. The overall regulatory profile is defined by the absence of documented clinically significant interactions with other medicines.

Q: What information is available for diabetic patients regarding Бронхипрет?

A: Diabetic patients should note that some formulations contain sugars or sugar substitutes like maltitol. Official patient information leaflets often contain specific notes detailing the sugar and carbohydrate content, which may require consideration for dietary management.

Q: Is it normal to feel a warming sensation in the throat after taking Бронхипрет?

A: A warming sensation in the throat is not listed as a documented side effect, but it is likely related to the presence of concentrated components. This could be due to the ethanol (alcohol) content and the potent essential oils from the Thyme extract.

Q: Does Бронхипрет have any known effect on liver enzymes?

A: The official product documentation does not provide information regarding effects on CYP enzymes or general drug clearance in the liver. This means no adverse effects on liver enzymes are documented in the official prescribing information.

Q: What liquids can be used to take Бронхипрет syrup?

A: Official administration instructions state that the syrup dose should be taken either undiluted or with some water. There is no specific regulatory guidance or information available concerning the dilution of the syrup with juice or other beverages.

Q: Are there specific instructions for administering Бронхипрет drops?

A: Yes, specific administration guidelines apply to the Drops formulation. These include a minimum recommended age for use, a defined dose, and a schedule of administration, typically three times daily.

Q: Does taking Бронхипрет affect sleep patterns?

A: Adverse effects related to the central nervous system (CNS) or changes to sleep patterns are not listed within the common or rare side effect profiles documented in the official regulatory safety information for the medicine.

Storage Conditions and Shelf-Life

Official regulatory documents mandate specific storage conditions for Bronchipret formulations to ensure stability.

• Temperature: The Syrup TE and Tablet TP forms must not be stored above 25 C. The unopened Drops formulation does not require a special temperature condition.
• Protection: Liquid formulations must be stored in the original container to protect the contents from light and should be kept tightly closed after each use. Tablets must be stored in a dry place.
• In-Use Stability: After the bottle is first opened, the Syrup and Drops liquid products are limited to a 6-month shelf life. The medicine must not be used after the expiry date on the packaging.
• Child Safety: All formulations must be kept out of the sight and reach of children.

Disposal Requirements

Expired or unused Bronchipret must be disposed of according to established pharmaceutical waste protocols. The product must not be thrown away via wastewater or household waste. Patients are instructed to consult a pharmacist regarding the proper disposal of unused medicine based on local regulations.